August 10, 2022
Pfizer Introduces Warranty Program for Rare Disease Drug Panzyga
Read More
April 14, 2022
ICER Draft Evidence Report on Bluebird Gene Therapy Zynteglo Finds It Provides Value at $2.1 Million
Read More
February 4, 2022
Orchard Therapeutics Reaches Agreement with NHS England for MLD Gene Therapy
Read More
October 20, 2021
ICER Finds Soliris for Myasthenia Gravis Far from Cost-Effective
Read More
April 21, 2021
Bluebird Withdraws Zynteglo from German Market, Cuts Workforce
Read More
August 31, 2020
ICER Finds BioMarin Gene Therapy Could Justify $2.5 Million Price Tag
Read More
April 29, 2020
ICER Praises CF Drug’s Benefits, but Says It’s Overpriced
Read More
February 21, 2020
The Lost Art of Letter Writing
Read More
February 18, 2020
First UK Patients Begin Gene Therapy Treatment for Blindness through NHS
Read More
January 28, 2020
FTC, N.Y. AG Sue Vyera Pharmaceuticals, Shkreli over Alleged Anticompetitive Scheme
Read More
January 22, 2020
Making the Value Proposition for Rare Disease Therapies
Read More
January 3, 2020
NICE Rejects Akcea’s FCS Drug Waylivra as Too Costly
Read More
Load More
X